Metronomic ASTX727 + Venetoclax (R/R AML, HR-MDS, HR/AP MPN)

Current understanding

A single-center randomized phase 2 trial is evaluating metronomic (low-dose continuous) oral decitabine-cedazuridine (ASTX727) combined with venetoclax in relapsed/refractory AML, higher-risk MDS, and high-risk/accelerated-phase MPN. The regimen extends the established HMA + BCL-2 inhibitor backbone into salvage settings and tests whether a metronomic schedule improves tolerability or sustained hypomethylation compared to standard 5-day ASTX727 dosing. Evidence is trial-early.

Evidence log

Open questions

Related